Dysport Dosing by Patient Age Loosens Grip of Crow's Feet

RHODES, GREECE — Botulinum toxin type A is a safe and effective treatment for crow's feet at doses of 15, 30, and 45 U per eye, Dr. Benjamin Ascher said in a poster presented at the 15th Congress of the European Academy of Dermatology and Venereology.

The 15-U dose appears to be an appropriate starting point for treatment in younger subjects, while the higher doses appear to provide greater benefit in older patients, said Dr. Ascher of the Hospital of St. Cloud, Paris.

A total of 220 adults aged 18–65 years were enrolled in the randomized, multicenter, double-blind, placebo-controlled dose-ranging study of botulinum toxin type A, which is available in Europe as Dysport and is currently in clinical trials under the name Reloxin in the United States. The subjects, who had moderate or severe crow's feet at maximum smile and mild to severe crow's feet at rest, were treated with placebo or 15, 30, or 45 U per eye. Efficacy and safety were evaluated at 2, 4, 8, 12, 16, 20, and 24 weeks following injection.

For all three doses of Dysport, compared with placebo, a highly significant difference in apparent severity of crow's feet at maximum smile was noted after 4 weeks, as determined by independent panel and "live" investigator assessments. At the 2- to 16-week follow-ups, the independent panel assessed the appearance of crow's feet at rest as being statistically significantly improved, compared with placebo, at the two higher doses of Dysport; live investigators assessed their appearance at rest to be significantly improved at all doses, Dr. Ascher said.

When results were considered according to age, those aged 50 years and younger were more likely than older patients to respond to all doses of Dysport. At week 2, between 9 and 12 patients (depending on dose) aged 51 and older were assessed by the independent panel as having significant improvement, compared with 17–20 subjects (depending on dose) aged 50 years and younger. In those aged 51 and older, the higher doses appeared to confer greater benefit, he said.

Patient satisfaction was good in this study, which was funded by Ipsen Ltd., the maker of Dysport.

Self-assessment of satisfaction with the change in crow's feet appearance was significantly greater with Dysport at all doses, compared with placebo, at up to 16 weeks' follow-up. The safety profile of Dysport was also good: 23 treatment-related adverse events were reported by 22 subjects, but none were serious and all resolved without sequelae.

RHODES, GREECE — Botulinum toxin type A is a safe and effective treatment for crow's feet at doses of 15, 30, and 45 U per eye, Dr. Benjamin Ascher said in a poster presented at the 15th Congress of the European Academy of Dermatology and Venereology.

The 15-U dose appears to be an appropriate starting point for treatment in younger subjects, while the higher doses appear to provide greater benefit in older patients, said Dr. Ascher of the Hospital of St. Cloud, Paris.

A total of 220 adults aged 18–65 years were enrolled in the randomized, multicenter, double-blind, placebo-controlled dose-ranging study of botulinum toxin type A, which is available in Europe as Dysport and is currently in clinical trials under the name Reloxin in the United States. The subjects, who had moderate or severe crow's feet at maximum smile and mild to severe crow's feet at rest, were treated with placebo or 15, 30, or 45 U per eye. Efficacy and safety were evaluated at 2, 4, 8, 12, 16, 20, and 24 weeks following injection.

For all three doses of Dysport, compared with placebo, a highly significant difference in apparent severity of crow's feet at maximum smile was noted after 4 weeks, as determined by independent panel and "live" investigator assessments. At the 2- to 16-week follow-ups, the independent panel assessed the appearance of crow's feet at rest as being statistically significantly improved, compared with placebo, at the two higher doses of Dysport; live investigators assessed their appearance at rest to be significantly improved at all doses, Dr. Ascher said.

When results were considered according to age, those aged 50 years and younger were more likely than older patients to respond to all doses of Dysport. At week 2, between 9 and 12 patients (depending on dose) aged 51 and older were assessed by the independent panel as having significant improvement, compared with 17–20 subjects (depending on dose) aged 50 years and younger. In those aged 51 and older, the higher doses appeared to confer greater benefit, he said.

Patient satisfaction was good in this study, which was funded by Ipsen Ltd., the maker of Dysport.

Self-assessment of satisfaction with the change in crow's feet appearance was significantly greater with Dysport at all doses, compared with placebo, at up to 16 weeks' follow-up. The safety profile of Dysport was also good: 23 treatment-related adverse events were reported by 22 subjects, but none were serious and all resolved without sequelae.

RHODES, GREECE — Botulinum toxin type A is a safe and effective treatment for crow's feet at doses of 15, 30, and 45 U per eye, Dr. Benjamin Ascher said in a poster presented at the 15th Congress of the European Academy of Dermatology and Venereology.

The 15-U dose appears to be an appropriate starting point for treatment in younger subjects, while the higher doses appear to provide greater benefit in older patients, said Dr. Ascher of the Hospital of St. Cloud, Paris.

A total of 220 adults aged 18–65 years were enrolled in the randomized, multicenter, double-blind, placebo-controlled dose-ranging study of botulinum toxin type A, which is available in Europe as Dysport and is currently in clinical trials under the name Reloxin in the United States. The subjects, who had moderate or severe crow's feet at maximum smile and mild to severe crow's feet at rest, were treated with placebo or 15, 30, or 45 U per eye. Efficacy and safety were evaluated at 2, 4, 8, 12, 16, 20, and 24 weeks following injection.

For all three doses of Dysport, compared with placebo, a highly significant difference in apparent severity of crow's feet at maximum smile was noted after 4 weeks, as determined by independent panel and "live" investigator assessments. At the 2- to 16-week follow-ups, the independent panel assessed the appearance of crow's feet at rest as being statistically significantly improved, compared with placebo, at the two higher doses of Dysport; live investigators assessed their appearance at rest to be significantly improved at all doses, Dr. Ascher said.

When results were considered according to age, those aged 50 years and younger were more likely than older patients to respond to all doses of Dysport. At week 2, between 9 and 12 patients (depending on dose) aged 51 and older were assessed by the independent panel as having significant improvement, compared with 17–20 subjects (depending on dose) aged 50 years and younger. In those aged 51 and older, the higher doses appeared to confer greater benefit, he said.

Patient satisfaction was good in this study, which was funded by Ipsen Ltd., the maker of Dysport.

Self-assessment of satisfaction with the change in crow's feet appearance was significantly greater with Dysport at all doses, compared with placebo, at up to 16 weeks' follow-up. The safety profile of Dysport was also good: 23 treatment-related adverse events were reported by 22 subjects, but none were serious and all resolved without sequelae.